Protocol FOR SWITCHING TO NEWER BASAL INSULINS

FROM:	TO:		
	Insulin Glargine 300 units/mL (Toujeo):	Glargine 100 units/mL (Basaglar):	Degludec (Tresiba)
Insulin glargine 300 units/mL (Toujeo) OD		Reduce by 20%*	Reduce by 20%*
Insulin glargine 100 units/mL (Lantus) OD	Same dose*	Same dose	Same dose**♯
Insulin glargine 100 units/mL (Lantus) BID	Same dose	Same dose BID	Reduce by 20%
Insulin detemir (Levemir) OD	Same dose	Same dose	Same dose ♯
Insulin detemir (Levemir) BID	Reduce by 20%	Reduce by 20%	Reduce by 20%
Insulin NPH OD	Same dose	Same dose	Same dose ♯
Insulin NPH BID	Reduce by 20%	Reduce by 20%	Reduce by 20%

*A 10–17% higher dose requirement with insulin glargine 300 units/mL vs. 100 units/mL has been observed. Therefore, a higher daily insulin glargine 300 units/mL dose may be needed to achieve target ranges for plasma glucose level.

**A small 3–4% lower dose requirement with insulin degludec vs. insulin glargine 100 units/mL has been observed in the SWITCH #For type 1 diabetes: reduce by 20%

1

TOUJEO[™]SoloSTAR® Product Monograph. Sanofi-aventis Canada, Inc. May 2015. BASAGLAR[™] Product Monograph. Eli Lilly Canada, Inc. September 2015.

DEGLUDEC™ Product Monograph. Novo Nordisk Canada Inc. August 2017.

Titration Protocols with Basal Insulins

	Basal			By who	FPG (mmol/L)													
	Insulin	Every	Based on	?	0	1	2	3	4	5		6	7	8	9	10) 11	
Treat to Target	Glargine	week	Mean preceding 2 days	nurse	0							+ 2	+ 6		+ 8			
EDITION trials	Glargine U300	week	Median last 3 days	nurse	- 3					0)	+	+ 3			+ 6		
BEGIN trials step-wise	Degludec	week	Lowest of last 3 days	nurse patient	- 4			- 2	0		+ + 2 4			+ 6	+ 8			
BEGIN simple step trial	Degludec	week	Same day measure	nurse patient	- 4				0		+ 4							
INSIGHT	Glargine U100 and U300	day	Same day measure	patient					0				+ 1					

1. Riddle MC, et al. Diabetes Care 2003;26:3080-86. 2. Bolli GB, et al. Diabetes Obes Metab 2015;17:386-94.

3. Philis-Tsimikas A, et al. Adv Ther 2013;30:607-22. 4. Gerstein HC, et al. Diabet Metab 2006;23:736-42.

5. Yale JF, et al. ADA Meeting. New Orleans, USA. 2016. Poster LBA-5918.